Press Releases

Date	Title	Company
22-Mar-2023	Dermapharm Holding SE: 2022 dividend	Dermapharm Holding SE
22-Mar-2023	NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)	Alnylam UK Limited
22-Mar-2023	New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing	AKL Therapeutics
22-Mar-2023	Aston University to take part in West Midlands Innovation Accelerator to spark growth and innovation	Aston University
22-Mar-2023	ABPI response to MHRA clinical trials framework	ABPI
22-Mar-2023	KITE’S YESCARTA® (AXICABTAGENE CILOLEUCEL) CAR T-CELL THERAPY DEMONSTRATES A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR INITIAL TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)	Kite
22-Mar-2023	Aptamer launches Optimer®-Fc as a new reagent solution for immunohistochemistry	Aptamer Group plc
22-Mar-2023	Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions	Vaccitech
22-Mar-2023	Global pharmaceutical company moves into life sciences hub White City Place	invoX Pharma Ltd
22-Mar-2023	Brainomix Receives FDA Clearance for Its Flagship Stroke AI Imaging Software	Brainomix
22-Mar-2023	Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis	Sanofi
22-Mar-2023	iO:M8 receives CE-IVD certification	PreciPoint GmbH
22-Mar-2023	NEW SURVEY SUGGESTS PUBLIC AWARENESS OF PHARMACY SERVICES AS LOW AS 13%	Charac
22-Mar-2023	Karen Winterhalter, Director of Onyx Health, included in the E2E Female 100 list in association with The Independent	Onyx Health
22-Mar-2023	Douglas GmbH: DOUGLAS accelerates growth with strict customer focus and targeted omni-channel set-up	Douglas GmbH
22-Mar-2023	Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™	Cosmo Pharmaceuticals N.V.
22-Mar-2023	PolyPeptide publishes invitation to the annual General Meeting 2023	PolyPeptide Group
22-Mar-2023	Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023	Relief Therapeutics Holding SA
22-Mar-2023	CD Formulation Supplies Active Ingredients, Antioxidants, and Chelating Chemicals for Cosmetic Industry	CD Formulation
22-Mar-2023	Alfa Chemistry Announces to Participate in the Upcoming Pittcon Conference & Exposition 2023	Alfa Chemistry